Back to overview

Reduction of antibiotic resistance - Co-administration of food-grade compounds

Scientists at Leiden University's Institute of Biology have found compounds that reduce antibiotic resistance in pathogenic bacteria.

In the absence of an antibiotic agent, such compounds have no/hardly any bactericidal effect. The compounds are food-grade. Co-administration together with existing drugs will potentiate their effect. This should allow us to re-use antibiotics that have now been abandoned to due to resistance problems. Currently, the scientists are seeking partnerships for the next stage of development.

The antibiotics market (over 40 billion USD) is hampered by the lack of new (approved) compounds to answer the growth of antibiotic resistance that poses an increasing threat to treat bacterial infections. Only two completely new classes of antibiotics have been introduced over the past 30 years: the oxazolidinone linezolid (Zyvox; Pfizer) in 2000 and the cyclic lipopeptide daptomycin (Cubicin; Cubist) in 2003. Current approaches are focussing on pro-drug   strategies,   species-specific   platforms  (identification of (new) specific targets/pathways), and mining untapped sources of natural compounds.

This current invention allows potentiating existing antibiotics by counteracting antibiotic resistance. While the activity of the compounds is broad, we have established their positive effect in particular for enhancing the efficacy of aminoglycosides and β-lactam antibiotics. The enablement is further helped by the fact that the compounds are food-grade.

Fig. 1. Potentiating sensitivity of B. subtilis to antibiotics

Key benefits

  • The  synergistic effect of the identified compounds allows re- use of   existing antibiotics that have been abandoned due to resistance problems
  • The compounds hat reduce resistance are food-grade

Applications

Antibiotic adjuvant strategies: use of natural compounds that reduce resistance to antibiotics

Development stage

  • Proof-of-concept. Further development involves identification and/or synthesis of derivatives with similar activity
  • Co-development of (novel) compounds that reduce resistance to antibiotics

Luris reference number

INV-031.041

Patent status

A  patent application has been filed

Data available on request

Non-confidential and confidential presentations are available upon request.

Further information

Frits Fallaux Senior Knowledge Broker (LU) +31-71-527 2517 f.j.fallaux@luris.nl